医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
4期
77-78
,共2页
哌拉西林-他唑巴坦%COPD%吸入性肺炎
哌拉西林-他唑巴坦%COPD%吸入性肺炎
고랍서림-타서파탄%COPD%흡입성폐염
Piperacil in-tazobactam%COPD%Aspiration Pneumonia
目的：评价哌拉西林-他唑巴坦治疗COPD合并吸入性肺炎（AP）的临床疗效和安全性。方法回顾性分析哌拉西林他唑巴坦治疗47例 COPD合并 AP患者的临床疗效、细菌学评价和安全性分析。结果哌拉西林他唑巴坦治疗COPD合并AP患者有效率为78.7%，痊愈率29.8%，细菌清除率为75.9%，不良反应发生率为4.3%。结论哌拉西林-他唑巴坦治疗COPD合并AP患者疗效好，安全性高。
目的：評價哌拉西林-他唑巴坦治療COPD閤併吸入性肺炎（AP）的臨床療效和安全性。方法迴顧性分析哌拉西林他唑巴坦治療47例 COPD閤併 AP患者的臨床療效、細菌學評價和安全性分析。結果哌拉西林他唑巴坦治療COPD閤併AP患者有效率為78.7%，痊愈率29.8%，細菌清除率為75.9%，不良反應髮生率為4.3%。結論哌拉西林-他唑巴坦治療COPD閤併AP患者療效好，安全性高。
목적：평개고랍서림-타서파탄치료COPD합병흡입성폐염（AP）적림상료효화안전성。방법회고성분석고랍서림타서파탄치료47례 COPD합병 AP환자적림상료효、세균학평개화안전성분석。결과고랍서림타서파탄치료COPD합병AP환자유효솔위78.7%，전유솔29.8%，세균청제솔위75.9%，불량반응발생솔위4.3%。결론고랍서림-타서파탄치료COPD합병AP환자료효호，안전성고。
Objective: To evaluate the ef icacy and safety of piperacil in-tazobactam in the treatment of patients with COPD complicated by aspiration pneumonia. Metheds: 47 patients with COPD complicated by aspiration pneumonia who were treated with piperacil in- tazobactam were enrol ed in this study by retrospective analysis. The treatment duration was 7-14 days.The clinical ef icacy, bacterial eradication rate, and safety were analyzed. Results: The total effective rate of piperacil in-tazobactam was 78.7% and the curative rate was 29.8%. The bacterial eradication rate was 75.9% while the rate of adverse effect was 4.3%. Conclusion: Piperacil in-tazobactam is effective and safe in the treatment of patients with COPD complicated by aspiration pneumonia.
